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Three-dimensional quantitative structure activity
relationship (3D-QSAR) study has been carried out
on the Escherichia coli DHFR inhibitors 2,4-diami-
no-5-(substituted-benzyl)pyrimidine derivatives to
understand the structural features responsible for
the improved potency. To construct highly predic-
tive 3D-QSAR models, comparative molecular field
analysis (CoMFA) and comparative molecular simi-
larity indices analysis (CoMSIA) methods were
used. The predicted models show statistically sig-
nificant cross-validated and non-cross-validated
correlation coefficient of r2CV and r
2
nCV , respectively.
The final 3D-QSAR models were validated using
structurally diverse test set compounds. Analysis
of the contour maps generated from CoMFA and
CoMSIA methods reveals that the substitution of
electronegative groups at the first and second posi-
tion along with electropositive group at the third
position of R2 substitution significantly increases
the potency of the derivatives. The results obtained
from the CoMFA and CoMSIA study delineate the
substituents on the trimethoprim analogues
responsible for the enhanced potency and also pro-
vide valuable directions for the design of new
trimethorpim analogues with improved affinity.
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Dihydrofolate reductase (DHFR) catalyzes the reduction of 5,6-dihy-
drofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF) using NADPH as a
cofactor (1,2). The DHFR also carries out the reduction of folate to
DHF; however, the reduction rate is comparatively slower than that of
DHF to THF. The resulting THF and other reduced folates act as cofac-
tors for various one-carbon transfer reactions such as the biosynthesis
of purines, thymidylate, panthothenate, and methionine that are
involved in the cell cycle. The DHFR enzyme is a potential drug target
for various conditions such as bacterial infection, malaria, and cancer
because of its association with the DNA synthesis (3,4). The essential
role of DHFR in DNA synthesis and in a variety of anabolic pathways
makes it a common target for antiproliferative therapeutics. Because
of its biological and pharmacological importance, DHFR has been the
subject of intensive structural and kinetic investigation over many
years, serving as a paradigm of enzymatic systems in many experi-
mental and theoretical studies (5–12). The thymidylate synthase cata-
lyzes the conversion of deoxyuridylate (dUMP) to deoxythymidylate
(dTMP) in which the dihydrofolates are generated as by-product (13).
The drugs targeted to DHFR are known as antifolates, and trimetho-
prim (TMP) is an antifolate that has high specificity to bacterial DHFR
over mammalian DHFR (3,14–17). The exposure of Escherichia coli
with TMP leads to rapid accretion of dihydrofolate, and it is further
oxidized into folates (1,8). The inhibitory activity of TMP analogous of
65 pyrimidine derivatives has been experimentally measured against
E. coli DHFR (ecDHFR) (18). The X-ray crystallography technique has
been extensively used to study the interactions of various TMP analo-
gous with the ecDHFR (19,20).
The majority of DHFR inhibitors described in the literature are derived
from various substitutions on 2,4-diaminopyrimidine derivatives. Sev-
eral QSAR studies have been performed on the pyrimidine derivatives
of ecDHFR (21–25). Czaplinski et al. have synthesized TMP analogues
with various 4-anilinoalkoxy moieties at the para position of phenyl
ring of pyrimidine derivatives and tested against ecDHFR (26). In addi-
tion, various QSAR models have also been developed for the same
set of derivatives. The nonlinear QSAR study on the pyrimidine deriva-
tives unveils important features of the data set and identifies three
distinct classes of molecules based on the mean activity values (27).
King et al. (28) have carried out QSAR study using the inductive logic
programming (ILP) procedure to discover new indicator variables for
pyrimidine derivatives against ecDHFR. The 3D-QSAR study on the
TMP analogues using the tensor representation method has unveiled
the geometrical information on the ecDHFR indirectly at the early
stages when the experimental geometries of the target are unavail-
able (29). The application of an adaptive neuro-fuzzy inference system
(ANFIS)-based QSAR models has been successfully derived for the
pyrimidine derivatives (30). The same derivatives have been used
to develop several neural network QSPR models using the Hansch
935
Chem Biol Drug Des 2012; 79: 935–942
Research Article
ª 2012 John Wiley & Sons A/S
doi: 10.1111/j.1747-0285.2012.01351.x
substituent constant predictor (31). Summerfield et al. have carried
out high-throughput screening of structurally diverse set of small mol-
ecules to identify new set of inhibitors for ecDHFR. They have identi-
fied several novel compounds that make interaction with the M20
loop of DHFR, and further the interaction was characterized using X-
ray crystallography and SAR analysis (9,11). Recently, Shine et al. (32)
have estimated the relative binding free energy of pyrimidine deriva-
tives (TMP and its analogues) with the ecDHFR based on a free
energy variational principle, and further they have derived a QSAR
model using the experimental free energy of binding.
Despite numerous QSAR studies have been carried out with differ-
ent approaches on the pyrimidine derivatives of ecDHFR, the appli-
cation of 3D-QSAR study that yields valuable information on the
design and development of new ligands is scarce. Despite there
are numerous inhibitors successfully targeted against DHFR to com-
bat a variety of bacterial infection and caner, still there is a need
to improve the inhibitory activity of TMP analogues. Hence, the 3D-
QSAR approach has been applied on these compounds using the
comparative molecular field analysis (CoMFA) (33,34) and compara-
tive molecular similarity indices analysis (CoMSIA) (35) methods.
The results obtained from this study could help in understanding
various structural features responsible for the activity of pyrimidine
derivatives and also provide useful information for the design and
synthesis of novel inhibitors.
Materials and Methods
Data set
The 2,4-diamino-5-(substituted-benzyl) pyrimidine derivatives of
ecDHFR inhibitors were used for the 3D-QSAR study (18). The data
set of 65 compounds with the corresponding inhibition constant (Ki)
values converted into pKi is shown in the Table 1. The data set is
further divided into training set and test set which includes 55 and
10 compounds, respectively. The test set compounds were randomly
chosen to represent the diversity in the structure and activity val-
ues. The training set compounds were used to build the 3D-QSAR
models by considering the pKi values as dependent variables, and
the predicted models were evaluated using the test set compounds.
Molecular modeling and alignment
The three-dimensional structures of all compounds were prepared
using the SYBYL 8.1.1 software of Tripos (36). Partial atomic charges
were calculated by the Gasteiger–Huckel method, (37) and energy
minimizations were performed using the Tripos force field and the
Powell conjugate gradient algorithm with a convergence criterion of
0.005 kcal ⁄mol . The compound 65 that is having lowest energy
was chosen as template molecule. The template molecule was used
to superimpose all the compounds with the application of database
alignment method. The atoms selected for the common substructure
alignment are shown with asterisks in Table 1.
CoMFA and CoMSIA analysis
The following standard procedures were used to calculate the CoM-
FA and CoMSIA descriptors. Each compound was inserted into a
Table 1: Data set of pyrimidine derivatives used for the 3D-
QSAR study
Compound R1 R2 R3 pK i
1 CH2CH3 CH2CH3 CH2CH3 7.82
2a OCH3 OCH2CH2OCH3 OCH3 8.35
3 OCH3 OCH3 OCH3 8.08
4a OCH3 N(CH3)2 OCH3 7.71
5 OCH3 Br OCH3 8.18
6 OCH3 SCH3 OCH3 8.07
7 OCH3 O(CH2)7CH3 OCH3 7.20
8 CH2OH H CH2OH 6.31
9 OCH3 H OCH3 7.71
10a OCH2CH3 H OCH2CH3 7.69
11 OCH2CH3 H OCH2CH2CH3 7.69
12a OCH2CH2CH3 H OCH2CH2CH3 7.41
13 CH3 H CH3 7.04
14 H OH OH 6.46
15 H NHCOCH3 NO2 6.97
16a H OCH2CH2OCH3 OCH2CH2OCH3 7.22
17 H OCH3 OCH3 7.72
18a H OCH3 OH 6.84
19 H OSO2CH3 OCH3 7.94
20a H OH OCH3 7.54
21a H OCH2CH2OCH3 OCH3 7.77
22a H OCH2C6H5 OCH3 7.53
23 H OCH3 OSO2CH3 7.80
24 OCH2C6H5 OCH3 H 7.66
25 CF3 OCH3 H 7.69
26 O(CH2)7CH3 OCH3 H 7.16
27 OCH2CH3 OCH2C6H5 H 7.35
28 H H OCH2CONH2 6.57
29 H H CH2OH 6.28
30 H H OSO2CH3 6.92
31 H H CH2OCH3 6.59
32 H H OH 6.47
33 H H OCH2CH2OCH3 6.53
34 H H OCH3 6.93
35 F H H 6.23
36 CH3 H H 6.70
37 Cl H H 6.65
38 Br H H 6.96
39 CF3 H H 7.02
40a CO(CH2)3CH3 H H 6.55
41 I H H 7.23
42 O(CH2)3CH3 H H 6.82
43 OCH2C6H5 H H 6.99
44 O(CH2)5CH3 H H 6.86
45 O(CH2)6CH3 H H 6.39
46 O(CH2)7CH3 H H 6.25
47 H NH2 H 6.30
48 H NHCOCH3 H 6.89
49 H OSO2CH3 H 6.60
50 H OH H 6.45
51 H OCH2CH2OCH3 H 6.40
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three-dimensional lattice with grid points separated by 2.0  in x,
y, and z directions and an extension of 4  beyond the aligned mol-
ecules in all directions. For the CoMFA analysis, the steric (van der
Waals) and electrostatic (Coulombic) field descriptors were calcu-
lated at all lattice points by adding the individual energy interac-
tions between each atom of the compound using an sp3 carbon
probe atom with +1 charge and 1.52  van der Waals radius. The
CoMFA cutoff values were set to 30 kcal ⁄mol for both steric and
electrostatic fields. The similarity indices were computed using a
probe atom with 1  radius and +1 atomic charge. The distance
dependence between the grid point and each atom of molecule
was determined by Gaussian function through the similarity indices
calculated at all grid points, and a default value of 0.3 was used
as an attenuation factor a. The value displayed for each CoMSIA
column is the root mean square deviation of the points that consti-
tute the field.
Partial least squares analysis
The descriptors calculated from the CoMFA and CoMSIA analysis
were used as independent variables, and the pKi values were used
as dependent variables in partial least squares (PLS) (38) analysis
to derive 3D-QSAR models using the standard implementation in
the SYBYL package. Linear regression equations were obtained by
the PLS technique, correlating changes in the steric and electro-
static fields (for CoMFA) and similarity fields (for CoMSIA) with
changes in the pKi values of the inhibitor sets. The cross-validation
in PLS analysis was performed by leave-one-out (LOO) procedure to
find the optimal number of components in building the regression
models and to check the statistical significance of the model. The
LOO method effectively evaluates the model by excluding one com-
pound from the data set at a time and measuring the internal pre-
dictive ability of the newly created model. The quality of the model
was expressed as the cross-validated correlation coefficient r 2CV .
The optimal number of components obtained from the LOO method
was used to derive the final model using non-cross-validated PLS
analysis. The correlation coefficient (r 2nCV ) was used to measure
the quality of the obtained final model. Column filtering, for any
column of computed energies with a variation less than 2.0 kcal ⁄
mol, was applied as needed to reduce computation time without
negatively affecting the quality of the models. The predictive power
of the models was evaluated first by leave-one-out (LOO) cross-vali-
dation (7,8). The non-cross-validated coefficient, r2CV , was calcu-
lated using eqn 1.
r 2nCV ¼ 1
Pn
i¼1
ðyi;observed  yi;predictedÞ2
Pn
i¼1
ðyi;observed  ymeanÞ2
ð1Þ
where yi,predicted, yi,observed, and ymean are predicted, actual, and
mean values of the target property (pKi), respectively. To test the
utility of the model as a predictive tool, an external set of com-
pounds with known activities but not used in model generation (the
test set) was predicted. The predictive squared correlation coeffi-
cient, r 2pred, calculated by using eqn 2, was based on molecules
from the test set, and it was used to evaluate the predictive power
of the CoMFA and CoMSIA models.
r 2pred ¼ ðSD PRESSÞ=SD ð2Þ
where SD is the sum of the squared deviations between the actual
activities of the compounds in the test set and the mean activity of
the compounds in the training set, and 'PRESS' is the sum of the
squared deviations between predicted and actual activities for every
compound in the test set. A r 2predvalue of 1 signifies that the CoM-
FA model is perfectly predictive for the test set, while prediction of
a mean value of the training set for every member in the test set
yields a predictive r2 = 0.
Results and Discussion
CoMFA and CoMSIA statistical results
The CoMFA and CoMSIA models were developed using the steric
and electrostatic descriptors. The statistical results obtained from
these models are presented in Table 2. The leave-one-out cross-val-
idated correlation coefficients (r 2CV ) for CoMFA and CoMSIA models
are 0.75 and 0.73, respectively. The supporting information Table S1
shows that the model attains significant r 2CV value with six compo-
nents. The non-cross-validated correlation coefficients (r 2nCV ) for
CoMFA and CoMSIA models are 0.95 and 0.88, respectively. The
low standard error of estimation (SEE) and high F values confirm
that the models are statistically significant to predict the inhibitory
activity of pyrimidine derivatives. The predicted steric and electro-
static contributions from the CoMFA and CoMSIA analysis are
64.5% and 35.5% as well as 57.1% and 42.9%, respectively. Evi-
dences indicate that the steric contributions are slightly higher than
the electrostatic contributions. To validate the predicted models, the
external test set compounds were used to assess the predictive
power of the models. The test set compounds are not included in
the prediction of CoMFA and CoMSIA models. The Tables 3 and 4
contain the predicted activities (pKi) for the training set and test
set compounds. The predictive correlation coefficient values (r 2pred )
for the CoMFA and CoMSIA models are 0.69 and 0.59, respectively.
The graphical results for the experimental verses predicted pKi
values of both training and test sets are displayed in Figure 1.
Table 1: Continued
Compound R1 R2 R3 pK i
52 H NO2 H 6.20
53 H OCH3 H 6.82
54 H F H 6.35
55 H N(CH3)2 H 6.78
56 H CH3 H 6.48
57 H Cl H 6.45
58 H Br H 6.82
59 H OCF3 H 6.57
60 H O(CH2)3CH3 H 6.89
61 H OCH2C6H5 H 6.89
62 H O(CH2)5CH3 H 6.07
63 H O(CH2)6CH3 H 6.10
64 H C6H5 H 6.93
65 H H H 6.18
aTest set compounds.
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Electrostatic contour map of CoMFA and
CoMSIA
The electrostatic red contours derived from the CoMFA and CoMSIA
imply the presence of negative charge favors the inhibitory activity.
On the other hand, the blue contours indicate the regions where
the occurrence of positive charge enhances the activity. In the elec-
trostatic field, the red and blue contours represent 80% and 20%
levels of contributions, respectively. The electrostatic contour map
obtained for the CoMFA and CoMSIA models is displayed in Fig-
ure 2. The large blue contours observed at the second and third
positions of R1 and R3 substitutions indicate that the presence of
electropositive groups at these positions increases the potency (Fig-
ure 2A). This observation is in agreement with the previous QSAR
study based on the hydrophobic and molar refractivity constants of
various R1, R2, and R3 substituents (18). The optimum value for the
hydrophobic constant is derived as 0.73 for R1 and R3 substitution.
In Figure 2, the first positions of the R1 and R2 substitutions are
surrounded by a large red contour. A small red contour is located
at the first position of R3 and second position of R2 substitutions
(Figure 2A). It shows that the presence of electronegative groups at
these positions favors the activity of the inhibitors. Figure 2A also
illustrates a small blue contour at the third position of the R2 sub-
stitution. The CoMSIA electrostatic contour shows (Figure 2B) small
and large red surfaces at the first position of R3 and R1 substitu-
tions, respectively. Figure 2B also displays a large blue surface at
the second and third positions of the R3 substitution and a small
blue surface at the third position of the R2 substitution. The
observed electrostatic contour maps from the CoMFA and CoMSIA
analysis for R1 and R3 substitutions clearly demonstrate that the
first position is highly preferred by the electronegative groups,
whereas the second and third positions are predominantly favored
by the electropositive groups. The substitution of –OCH3 group at
the R1 and R3 substitutions induces positive potential at the second
position, and further lengthening of the chain with hydrocarbons
enhances the positive potential at this position. This can be further
interpreted that the presence of O atom at the first position
attracts the electron clouds from the –CH3 as well as from the
adjacent phenyl group and thus leading to negative potential at
the O atom and positive potential at the –CH3 group. In fact, the
Table 3: Observed and predicted activities (pKi) of training set
CoMFA and CoMSIA models
Compound Exp. pKi
CoMFA CoMSIA
Predicted Residual Predicted Residual
1 7.82 7.72 0.10 7.69 0.13
3 8.08 8.31 0.23 8.37 0.29
5 8.18 8.01 0.18 7.90 0.28
6 8.07 8.22 0.15 8.24 0.17
7 7.20 7.21 0.01 7.21 0.01
8 6.31 6.40 0.09 6.62 0.31
9 7.71 7.68 0.03 7.72 0.01
11 7.69 7.69 0.00 7.82 0.13
13 7.04 6.98 0.06 6.84 0.20
14 6.46 6.47 0.01 6.69 0.23
15 6.97 6.90 0.07 6.98 0.00
17 7.72 7.67 0.05 7.60 0.12
19 7.94 7.61 0.33 7.70 0.24
23 7.80 7.78 0.02 7.53 0.27
24 7.66 7.46 0.20 7.69 0.03
25 7.69 7.72 0.03 7.57 0.12
26 7.16 7.11 0.05 7.05 0.11
27 7.35 7.48 0.13 7.26 0.09
28 6.57 6.59 0.02 6.63 0.06
29 6.28 6.12 0.16 6.40 0.12
30 6.92 6.99 0.07 6.95 0.02
31 6.59 6.36 0.23 6.42 0.17
32 6.47 6.40 0.07 6.50 0.03
33 6.53 6.61 0.08 6.49 0.04
34 6.93 6.94 0.01 7.05 0.12
35 6.23 6.31 0.08 6.60 0.37
36 6.70 6.87 0.17 6.61 0.09
37 6.65 6.61 0.04 6.54 0.11
38 6.96 6.83 0.13 6.54 0.42
39 7.02 7.12 0.10 6.95 0.07
41 7.23 6.91 0.32 6.56 0.67
42 6.82 6.90 0.08 6.98 0.16
43 6.99 7.04 0.05 7.06 0.07
44 6.86 6.74 0.12 6.64 0.22
45 6.39 6.54 0.15 6.48 0.09
46 6.25 6.30 0.04 6.38 0.13
47 6.30 6.31 0.01 6.56 0.26
48 6.89 6.90 0.01 6.92 0.03
49 6.60 6.85 0.25 7.00 0.40
50 6.45 6.33 0.12 6.46 0.01
51 6.40 6.69 0.29 6.44 0.04
52 6.20 6.23 0.03 6.21 0.01
53 6.82 6.82 0.00 6.91 0.09
54 6.35 6.35 0.00 6.49 0.14
55 6.78 6.74 0.04 6.75 0.03
56 6.48 6.49 0.01 6.63 0.15
57 6.45 6.49 0.04 6.48 0.03
58 6.82 6.64 0.18 6.49 0.33
59 6.57 6.70 0.13 6.67 0.10
60 6.89 6.77 0.12 6.71 0.18
61 6.89 7.08 0.19 6.88 0.01
62 6.07 6.25 0.18 6.18 0.10
63 6.10 6.11 0.01 5.96 0.14
64 6.93 6.95 0.02 7.06 0.13
65 6.18 6.12 0.06 6.36 0.18
Exp., experimental activity; CoMFA, comparative molecular field analysis;
CoMSIA, comparative molecular similarity indices analysis.
Table 2: Statistical summary of CoMFA and CoMSIA models
Parameter CoMFA CoMSIA
r2CV 0.75 0.73
r2nCV 0.95 0.88
r2pred 0.69 0.59
SEE 0.14 0.21
F-test 145.01 59.93
NC 6 6
Steric contribution (%) 64.50 57.10
Electrostatic contribution (%) 35.50 42.90
r 2CV , cross-validated correlation coefficient by PLS LOO method, r
2
nCV , non-
cross-validated correlation coefficient, r 2pred:; predicted correlation coeffi-
cient for the test set compounds, SEE, standard error of estimate, NC, opti-
mum number of components as obtained from the cross-validation study;
CoMFA, comparative molecular field analysis; CoMSIA, comparative molecu-
lar similarity indices analysis.
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negative potential at the O atom of –OCH3 group is further
strengthened by the mixing of O atom lone pair electrons with the
p-electron clouds of the phenyl ring. The absence of this intrinsic
property is evidenced by the lower activity for the compounds 13
and 65 that consist of –CH3 and H substitutions at R1 and R3 posi-
tion. The absence of O atom at the first position leads to less posi-
tive potential at the –CH3 and H groups of R1 and R3 substitution
which significantly reduces the potency of these compounds. It is
further evident by the presence of negative potential at the first
position and absence of positive potential at the second position or
negative potential at the second position of R1 and R3 substitutions
such as compounds 8, 14, 15, 18, 25, 29, 32, 35, 37–39, and
41 that show considerably lower activity. In addition, the substitu-
tion of –OCH3 group only at the R3 position retains moderate activ-
ity (compounds 17, 19–22) when compared to the –OCH3 groups
substituted at both R1 and R3 positions (compounds 2–7, 9). It is
interesting to note that compounds 47–65 have hydrogen substitu-
tion at the R1 and R3 positions, and hence, it shows significantly
lower activity. It can be seen from the compound 8 that the substi-
tution of –CH2OH at the R1 and R3 position, which is deficient of
the electropositive group at the second position, leads to lower
activity. This observation reiterates that the R1 and R3 substitutions
play a dominant role in the activity of pyrimidine derivatives that
prefers electronegative groups at the first position and electroposi-
tive groups at the second and third positions.
The observed red contour at the first position of the R2 substitution
shows that the presence of electronegative group improves the
potency, and further a small red contour is located at the second
position of the R2 substitution. The presence of electronegative
group at the second position of R2 substitution gives moderate
activity that is apparent from the activity of the compound 19. In
addition, a small blue surface located at the third position of R2
substitution indicates the presence of electropositive group
enhances the activity. It can be noted that the substitution of differ-
ent halogen groups at R1 (compounds 35, 37, 38, and 41) and R2
(compounds 5, 54, 57, and 58) positions exhibits variable activity.
It can be observed that the activity decreases with the increase in
the electronegativity of the halogen substituent. The order of the
halogen groups at R1 and R2 position that favors the activity is
I > Br > Cl > F. This observation can be correlated with the absence
of the positive potentials at the second position of R1 substitution.
In the case of halogen group substitution at the R2 position, the
compound 5 is substituted with Br at the R2 first position and –
OCH3 at the R1 and R3 positions, which shows the inhibitory activ-
ity of 8.18, while the other compounds with halogen substitutions
at the R2 position, compounds 54, 57, and 58, contain H substitu-
tion at the R1 and R3 with comparatively less activity than that of
compound 5. It is obvious on the basis of favored order of halogen
groups at R1 and R2 with improved potency, the present study sug-
gests that the substitution of I group at the R2 position of com-
pound 5 could further improve the inhibitory potency.
Steric contour map of CoMFA and CoMSIA
The steric contour maps observed using CoMFA and CoMSIA analy-
sis are presented in Figure 2. The green and yellow contours stand
for the sterically favorable (80% contribution) and unfavorable (20%
contribution) regions, respectively. The large green contours
Table 4: Observed and predicted activities (pKi) of test set CoM-
FA and CoMSIA models
Compound Exp. pKi
CoMFA CoMSIA
Predicted Residual Predicted Residual
2 8.35 7.96 0.39 7.87 0.48
4 7.71 8.32 0.61 8.51 0.80
10 7.69 7.79 0.10 7.81 0.12
12 7.41 7.64 0.23 7.79 0.38
16 7.22 7.09 0.13 6.62 0.60
18 6.84 7.12 0.28 7.06 0.22
20 7.54 7.10 0.44 7.29 0.25
21 7.77 7.39 0.38 7.14 0.63
22 7.53 7.72 0.19 7.56 0.03
40 6.55 7.35 0.80 7.14 0.58
CoMFA, comparative molecular field analysis; CoMSIA, comparative molecu-
lar similarity indices analysis.
A
B
Figure 1: Comparison of experimental versus predicted pKi val-
ues obtained from CoMFA (A) and CoMSIA (B) study.
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observed at second and third positions of R1 and R2 substitutions
reveal that the bulky group substituents at these regions improve
the inhibitory activity. It is further supported by the moderate activ-
ity observed for the bulky group substituents at the R1 and R2 posi-
tions such as compounds 4, 19, 22, 24, and 27. Several yellow
contours located at the terminals of the R1 substitution (Fig-
ure 2A,B) highlights that the lengthening of the chain does not
favor the potency of the inhibitors. It is clear from the lower activ-
ity of the compounds 26, 44–46 with extended chains at the R1
substitution. The large yellow surfaces (Figure 2) located at the
terminal of the R2 substitution reveals that the extended chain sub-
stituents at this position reduce the potency of the compounds. The
extended chain substituents at the R2 position such as compounds
51, 60–63 possess lower activity. In contrary, the compounds 7,
16, and 21 with extended chain substituents at the R2 position
exhibit moderate activity. The reduced activity observed for the
compounds 51, 60–63 can be attributed because of the presence
of hydrogen substitutions at the R1 and R3 positions. Figure 2A
shows a large yellow contour at the first position of the R3 substi-
tution which signifies that the bulky group substituents are not
favored at this position. In the case of compound 15, the substitu-
tion of branched chain substituent –NO2 at the R3 position does
not favors the potency of the compound. A small green contour
placed at the second position of the R3 substitution highlights that
the occurrence of the bulky group at this position favors the activity
of the compound.
Conclusion
In the present work, 3D-QSAR study has been carried out to
understand the structural features responsible for the potency of
the pyrimidine derivatives against ecDHFR. The CoMFA and CoM-
SIA models were established using the steric and electrostatic
descriptors, and the statistical significance of the obtained mod-
els is ensured with the high values of r 2CV and r
2
nCV . The reli-
ability of the predicted models is validated using the test set
compounds, and the predictive correlation coefficient (r 2pred ) con-
firms the high predictive power of the predicted models. It can
be observed from the statistical results that the CoMFA model
has better predictive ability than the CoMSIA model. The pre-
dicted CoMFA ⁄ CoMSIA field distributions show reasonable consis-
tency. The interpretation of various contour maps reveals that
the substitution of electronegative groups at the first and second
position along with electropositive group at the third position of
R2 substitution significantly increases the potency of the deriva-
tives. The presence of negative potential at the first position
and positive potential at the second position of R1 and R3 sub-
stitution favors the inhibitory activity. The substitution of
extended aliphatic chains at the R2 position does not favor the
inhibitory activity. The investigation of pyrimidine derivatives of
ecDHFR using 3D-QSAR method provides significant structural
information required to optimize the inhibitory activity.
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